Skip to main content

Table 1 Demographic and clinical characteristics

From: Psychometric properties of the osteoporosis assessment questionnaire (OPAQ) 2.0: results from the multiple outcomes of raloxifene evaluation (MORE) study

Parameter

Value

Sample size, N

1477

Age, years, mean (SD)

68.42 (6.81)

Body mass index, kg/cm 2 , mean (SD)

25.73 (4.34)

Years postmenopause, mean (SD)

20.94 (8.65)

Racial origin, white, n (%)

1417 (96%)

Prevalent vertebral fracture a , n (%)

1038 (70%)

Femoral neck BMD T-scores, mean (SD), [min, max]

−2.39 (0.57), [−4.5, 0.03]

Country of origin, n (%)

 

Australia

63 (4.3%)

Canada

116 (7.9%)

New Zealand

21 (1.4%)

United States

1277 (86%)

Smoking status a (yes vs. no, n)

180 vs. 1271

Alcohol consumption (yes vs. no, n)

306 vs. 1171

Number of prevalent vertebral fracture a

 

Mean (SD)

1.32 (1.38)

>Zero vs. zero

1038 vs. 439

Number of osteoporotic nonvertebral fracture

 

Mean (SD)

0.98 (1.24)

>Zero vs. zero

797 vs. 680

Baseline lumbar spine BMD, mean (SD), [min, max]

−2.51 (1.20), [−6.0, 3.0]

Family history of osteoporosis (yes vs. no/unknown)

469 vs. 1008

History of hysterectomy (yes vs. no, n)

411 vs. 1066

Marital status a (married vs. other, n)

823 vs. 648

Years of education, mean (SD)

13.81 (3.03)

Number of preexisting conditions, mean (SD)

10.37 (5.92)

  1. Abbreviations: BMD = bone mineral density; min = minimum; max = maximum; n/N = number; SD = standard deviation; vs. = versus.
  2. aTwenty-six subjects had no record of smoking status; six subjects had no record of marital status; three subjects had no record regarding number of prevalent vertebral fracture.